Liraglutide is approved in Europe for patients with T2DM and mild or moderate kidney damage, but is currently not recommended or should be used with caution in patients with severe renal impairment (130)
Anderson, K
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
Its about something almost no one in rheumatology is publicly discussing yet microdosing GLP-1 medications for psoriatic arthritis
As of January 6, 2025 here is a list of approved and pending new GLP-1 agonists class of medications that can help manage Type 2 diabetes and obesity: Ozempic (semaglutide) Approved - A weekly injectable GLP-1 receptor agonist that helps regulate blood sugar and suppress appetite, promoting weight loss in addition to managing type 2 diabetes
This has unlocked a new supply source for these drugs, and telehealth companies have taken notice and capitalized on it
